Lynparza (olaparib) Approved in the US as a First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

30 December 2019 -- AstraZeneca and Merck& Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that Lynparza® (olaparib) has been approved in the US for the maintenance treatment of adult patients...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news